GANX
Gain Therapeutics Inc.
$1.96
+$0.20(+11.36%)
54
Overall
40
Value
91
Tech
31
Quality
Market Cap
$56.80M
Volume
1.14M
52W Range
$1.41 - $2.81
Target Price
$7.43
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $165.0K | $140.1K | $55.2K | -- | ||
| Total Revenue | $165.0K | $140.1K | $55.2K | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $165.0K | $140.1K | $55.2K | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $14.0M | $17.9M | $22.3M | $20.4M | ||
| Research & Development | $7.2M | $8.4M | $11.5M | $10.8M | ||
| Research Expense | $7.2M | $8.4M | $11.5M | $10.8M | ||
| Selling, General & Administrative | $6.8M | $9.5M | $10.8M | $9.6M | ||
| General & Administrative Expenses | $6.8M | $9.5M | $10.8M | $9.6M | ||
| Salaries & Wages | -- | -- | $3.3M | $2.4M | ||
| Depreciation & Amortization | $15.5K | $26.6K | $35.0K | $38.0K | ||
| Depreciation & Amortization | $15.5K | $26.6K | $35.0K | $38.0K | ||
| Amortization | -- | $37.5K | $46.0K | $47.0K | ||
| Other Operating Expenses | $191.3K | -- | $246.2K | $229.1K | ||
| OPERATING INCOME | ||||||
| Operating income | $-13.8M | $-17.8M | $-22.3M | $-20.4M | ||
| EBITDA | $-13.9M | $-17.7M | $-22.1M | $-19.8M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $-12.5K | $-375.4K | $-494.2K | -- | ||
| Intinc | -- | -- | $494.2K | $357.1K | ||
| Net Non-Operating Interest Income/Expense | $12.5K | $375.4K | $494.2K | $357.1K | ||
| Other Income/Expense | $-937.0K | $-96.1K | $-429.3K | -- | ||
| Other Special Charges | $937.0K | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-13.9M | $-17.8M | $-22.2M | $-19.9M | ||
| Pre-Tax Income | $-13.9M | $-17.5M | $-22.2M | $-19.9M | ||
| INCOME TAX | ||||||
| Tax Provision | $4.0K | $93.0K | $79.3K | $536.8K | ||
| NET INCOME | ||||||
| Net Income | $-13.9M | $-17.6M | $-22.3M | $-20.4M | ||
| Net Income (Continuing Operations) | $-13.9M | $-17.6M | $-22.3M | $-20.4M | ||
| Net Income (Discontinued Operations) | $-13.9M | $-17.6M | $-22.3M | $-20.4M | ||
| Net Income (Common Stockholders) | $-13.9M | $-17.6M | $-22.3M | $-20.4M | ||
| Normalized Income | $-11.0M | -- | -- | $-19.7M | ||
| TOTALS | ||||||
| Total Expenses | $14.0M | $17.9M | $22.3M | $20.4M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $10.2M | $11.9M | $13.0M | $22.9M | ||
| Average Shares Outstanding (Diluted) | $10.2M | $11.9M | $13.0M | $22.9M | ||
| Shares Outstanding | $11.9M | $11.9M | $16.2M | $27.8M | ||
| Basic EPS | $-1.37 | $-1.48 | $-1.71 | $-0.89 | ||
| Basic EPS (Continuing Operations) | $-1.37 | $-1.48 | $-1.71 | $-0.89 | ||
| Diluted EPS | $-1.37 | $-1.48 | $-1.71 | $-0.89 | ||
| Diluted EPS (Continuing Operations) | $-1.37 | $-1.48 | $-1.71 | $-0.89 | ||
| OTHER METRICS | ||||||
| Other Gand A | $6.8M | $9.5M | $10.8M | $9.6M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GANX | $1.96 | +11.4% | 1.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |